Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to observe and evaluate the cost-effectiveness,efficacy and safety of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia(CIN) of cancer patients in the real world.1000 patients with non-myeloid malignancy who is planned to receive PEG-rhG-CSF for CIN prevention and 500 patients with non-myeloid malignancy who is planned to receive rhG-CSF for CIN prevention or treatment were prospectively recruited.The primary outcome was cost-effectiveness and second outcome was febrile neutropenia,the incidence and duration of grade IV neutropenia,chemotherapy delay,incidence of reduced dose of chemotherapy and relative dose intensity of chemotherapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03846414
Study type Observational
Source CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Contact Sun Guoping
Phone 13805609309
Email sunguoping@ahmu.edu.cn
Status Not yet recruiting
Phase
Start date February 13, 2019
Completion date October 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT02643901 - Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects Phase 1
Completed NCT02251977 - Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer Phase 3
Terminated NCT02454530 - Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
Active, not recruiting NCT02104830 - Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients Phase 3
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Active, not recruiting NCT03294577 - Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia Phase 3
Not yet recruiting NCT03701841 - Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis
Completed NCT00776165 - Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF) Phase 3
Completed NCT03251768 - Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients Phase 2
Recruiting NCT04101760 - Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Phase 3
Completed NCT04134429 - Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
Completed NCT04227990 - Plinabulin iv Solution in Prevention of TAC Induced Neutropenia Phase 2
Completed NCT03102606 - Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 Phase 3
Completed NCT01569087 - Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients Phase 2
Completed NCT05512676 - Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
Completed NCT04460079 - Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
Recruiting NCT02725606 - Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer Phase 1
Completed NCT02692742 - Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia Phase 2
Completed NCT02532712 - Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers Phase 1
Completed NCT01516736 - Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim Phase 3